Trial · NCT00860158
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
NCT00860158, Phase 2, Terminated, Noah Hahn, M.D.; results first posted 2016-02-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer. Trials, record NCT00860158. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00860158
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
- NCT number
- NCT00860158
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Noah Hahn, M.D.
- Conditions
- Prostate Cancer
- Interventions
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- First posted
- 2009-03-12
- Last updated
- 2018-03-14
- Results first posted
- 2016-02-05
- Limitations and caveats
- This study was terminated due to slow accrual and no results were analyzed.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To Estimate the Pathologic Complete Response (pCR) Rate | 18 months | |
| Secondary | To Estimate Partial Pathologic Responses (pPR) | 18 months | |
| Secondary | To Estimate PSA Response Rate | 18 months | |
| Secondary | To Estimate Progression Free Survival | 18 months | |
| Secondary | To Evaluate the Impact of Dasatinib Plus LHRH on Expression of Selected Biomarkers | 18 months | |
| Secondary | To Estimate Safety and Tolerability of LHRH Plus Dasatinib | 18 months |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | To Estimate the Pathologic Complete Response (pCR) Rate | 18 months | No participants were analyzed for pCR due to study termination | ||
| SECONDARY | To Estimate Partial Pathologic Responses (pPR) | 18 months | |||
| SECONDARY | To Estimate PSA Response Rate | 18 months | Data for this secondary objective was not collected or analyzed. | ||
| SECONDARY | To Estimate Progression Free Survival | 18 months | |||
| SECONDARY | To Evaluate the Impact of Dasatinib Plus LHRH on Expression of Selected Biomarkers | 18 months | |||
| SECONDARY | To Estimate Safety and Tolerability of LHRH Plus Dasatinib | 18 months |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental Arm | 1 | |
| Overall Study | COMPLETED | Experimental Arm | 0 | |
| Overall Study | NOT COMPLETED | Experimental Arm | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | DIARRHEA | Gastrointestinal disorders | Single Arm Assignment | 1 | 1 | 1 |
| other | FATIGUE (ASTHENIA, LETHARGY, MALAISE) | General disorders | Single Arm Assignment | 1 | 1 | 1 |
| other | NAUSEA | Gastrointestinal disorders | Single Arm Assignment | 1 | 1 | 1 |
| other | TASTE ALTERATION (DYSGEUSIA) | Gastrointestinal disorders | Single Arm Assignment | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Single Arm Assignment | ||
| Total, other adverse events | Single Arm Assignment | 1 | 1 |
| Total, serious adverse events | Single Arm Assignment | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00860158
GET https://conductscience.org/api/trials/v1/NCT00860158/registered